Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation

Loss-of-function mutations of EZH2, a catalytic component of polycomb repressive complex 2 (PRC2), are observed in ~\n10% of patients with myelodysplastic syndrome (MDS), but are rare in acute myeloid leukaemia (AML). Recent studies have shown that EZH2 mutations are often associated with RUNX1 muta...

Full description

Saved in:
Bibliographic Details
Published in:Nature communications 2014-06, Vol.5, p.4177
Main Authors: Sashida, Goro, Harada, Hironori, Matsui, Hirotaka, Oshima, Motohiko, Yui, Makiko, Harada, Yuka, Tanaka, Satomi, Mochizuki-Kashio, Makiko, Wang, Changshan, Saraya, Atsunori, Muto, Tomoya, Hayashi, Yoshihiro, Suzuki, Kotaro, Nakajima, Hiroshi, Inaba, Toshiya, Koseki, Haruhiko, Huang, Gang, Kitamura, Toshio, Iwama, Atsushi
Format: Article
Language:English
Subjects:
Animals
Bone Marrow Cells - enzymology
Cell Transformation, Neoplastic
Core Binding Factor Alpha 2 Subunit - genetics
Core Binding Factor Alpha 2 Subunit - metabolism
Disease Models, Animal
Disease Progression
Enhancer of Zeste Homolog 2 Protein
Female
Homeodomain Proteins - genetics
Homeodomain Proteins - metabolism
Humans
Leukemia, Myeloid, Acute - enzymology
Leukemia, Myeloid, Acute - genetics
Leukemia, Myeloid, Acute - pathology
Male
Mice
Mice, Inbred C57BL
Mice, Knockout
Myelodysplastic Syndromes - enzymology
Myelodysplastic Syndromes - genetics
Myelodysplastic Syndromes - pathology
Polycomb Repressive Complex 2 - deficiency
Polycomb Repressive Complex 2 - genetics
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Loss-of-function mutations of EZH2, a catalytic component of polycomb repressive complex 2 (PRC2), are observed in ~\n10% of patients with myelodysplastic syndrome (MDS), but are rare in acute myeloid leukaemia (AML). Recent studies have shown that EZH2 mutations are often associated with RUNX1 mutations in MDS patients, although its pathological function remains to be addressed. Here we establish an MDS mouse model by transducing a RUNX1S291fs mutant into hematopoietic stem cells and subsequently deleting Ezh2. Ezh2 loss significantly promotes RUNX1S291fs-induced MDS. Despite their compromised proliferative capacity of RUNX1S291fs/Ezh2-null MDS cells, MDS bone marrow impairs normal hematopoietic cells via selectively activating inflammatory cytokine responses, thereby allowing propagation of MDS clones. In contrast, loss of Ezh2 prevents the transformation of AML via PRC1-mediated repression of Hoxa9. These findings provide a comprehensive picture of how Ezh2 loss collaborates with RUNX1 mutants in the pathogenesis of MDS in both cell autonomous and non-autonomous manners.
ISSN:2041-1723
DOI:10.1038/ncomms5177